Jazz Pharmaceuticals plc — Director's Dealing 2022

Jun 8, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2022-06-06

Reporting Person: Iannone Robert (EVP, Global Head of R&D)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-06	Ordinary Shares	F	1295	$149.25	Disposed	38109	Direct

Footnotes

F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

F2: Includes 147 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2022.